Gain Therapeutics reports Phase 1b extension: GluSph down 81%, 4.8-pt MDS-UPDRS difference

Gain Therapeutics, Inc.

16 of 19 Part 1 participants continued into 9-month extension; all 16 remain on study at Day 150.
In participants with elevated baseline CSF GluSph, levels dropped an average of 81% after 90 days.
At Day 150, high-baseline GluSph group showed 4.8-point greater improvement in MDS-UPDRS Parts II+III vs low-baseline group.
Unsolicited patient reports: improved smell/taste (4), balance/gait (4), and sleep (3) after 90 days.
Planned Phase 2 will add UPSIT smell test and Opal wearable gait assessments as endpoints.

item 8.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-066062
form_type: 8-K
ticker: GANX
cik: 0001819411
company_name: Gain Therapeutics, Inc.
filed_at: 2026-05-26T13:26:00+00:00
discovered_at: 2026-05-26T13:27:00.482147+00:00
generated_at: 2026-05-26T13:27:43.981584+00:00
sec_items: ["8.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-066062
json_url: https://secwatch.observer/filing/0001104659-26-066062.json
markdown_url: https://secwatch.observer/filing/0001104659-26-066062.md
text_url: https://secwatch.observer/filing/0001104659-26-066062.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/0001104659-26-066062-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/tm2615594d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-066062

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.